Zobrazeno 81 - 90
of 695
pro vyhledávání: '"Mark A Wainberg"'
Autor:
Mark A. Wainberg, Bluma G. Brenner
Publikováno v:
AIDS (London, England). 30(17)
Autor:
Mark A. Wainberg, Thibault Mesplède
Publikováno v:
Infectious Diseases and Therapy
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by
Autor:
Guojun Wu, Xiaojian Yao, Shuiping Liu, Liyu Chen, Gary P. Kobinger, Mark A. Wainberg, Zhujun Ao, Kallesh Danappa Jayappa
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:3547-3554
In the absence of an effective vaccine against HIV-1 infection, anti-HIV-1 strategies play a major role in disease control. However, the rapid emergence of drug resistance against all currently used anti-HIV-1 molecules necessitates the development o
Autor:
Jan Münch, Mark A. Wainberg, Thibault Mesplède, Daniel A. Donahue, Björn D. Kuhl, Richard D Sloan
Publikováno v:
Journal of Virology. 87:8110-8123
HIV-1 can be transmitted as cell-free virus or via cell-to-cell contacts. Cell-to-cell transmission between CD4 + T cells is the more efficient mode of transmission and is predominant in lymphoid tissue, where the majority of virus resides. Yet the c
Autor:
Mark A. Wainberg, Bluma G. Brenner
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 63:S248-S254
The success of the HIV Prevention Trials Network 052 trial has led to revisions in HIV-1 treatment guidelines. Antiretroviral therapy may reduce the risk of HIV-1 transmissions at the population level. The design of successful treatment as prevention
Autor:
Susan M. Schader, Mark A. Wainberg, Eugene L. Asahchop, Susan P. Colby-Germinario, Hongtao Xu, Maureen Oliveira, Matthew McCallum, Stefan G. Sarafianos, Yudong Quan, Ying-Shan Han
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:3100-3109
Impacts of mutations at position E138 (A/G/K/Q/R/V) alone or in combination with M184I in HIV-1 reverse transcriptase (RT) were investigated. We also determined why E138K is the most prevalent nonnucleoside reverse transcriptase inhibitor mutation in
Autor:
Anders Sönnerborg, José M. Gatell, Ravindra K. Gupta, Mark A. Wainberg, Jean B. Nachega, Jan Albert, Françoise Brun-Vézinet
Publikováno v:
Journal of Infectious Diseases
Journal of Infectious Diseases; Vol 207
Journal of Infectious Diseases; Vol 207
Recent data from studies on treatment as prevention (TasP) and preexposure prophylaxis (PrEP) show that antiretroviral drugs can be used in prevention, as well as in treatment. The movement from first-generation antiretroviral therapy (ART) coformula
Autor:
Wei-Lie Xiao, Peter K. Quashie, Eric Deprez, Olivier Delelis, Jian-Xin Pu, Han-Dong Sun, Hongtao Xu, Mark A. Wainberg, Ying-Shan Han, Thibault Mesplède
Publikováno v:
Antiviral Research. 98:441-448
Human immunodeficiency virus integrase (HIV-1 IN) inhibitors that are currently approved or are in advanced clinical trials specifically target the strand transfer step of integration. However, considerable cross-resistance exists among some members
Autor:
Mark A. Wainberg, Yi-Ming Shi, Zhong-Hua Gao, Han-Dong Sun, Wei-Lie Xiao, Xue Du, Ying-Shan Han, Shang Shanzhai, Cheng-Qin Liang
Publikováno v:
Natural Products and Bioprospecting
Four new tetrahydrofuran lignans, schpropinrins A-D (1–4), together with five known ones, were isolated from the leaves and stems of Schisandra propinqua var. sinensis. Their structures, including absolute configurations, were characterized by mean
Publikováno v:
Current Opinion in Infectious Diseases. 26:43-49
Purpose of review Integrase strand transfer inhibitors (INSTIs) have become a key component of antiretroviral therapy since the approval of twice-daily raltegravir in 2007 and the more recent approval of elvitegravir in 2012. At the same time, a thir